Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WOLF Trial
NCT07423078Phase 2Recruiting
- Start
- Apr 2026
- Primary completion
- Apr 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in head and neck squamous cell carcinoma (HNSCC), laryngeal squamous cell carcinoma (LSCC), hypopharyngeal squamous cell carcinoma (HSCC). Started Apr 2026; status: recruiting.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)laryngeal squamous cell carcinoma (LSCC)hypopharyngeal squamous cell carcinoma (HSCC)
Beyond the preview
Go deeper on NCT07423078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07423078.